Topamax and hair loss is a concern raised by many patients prescribed topiramate for epilepsy or migraine prevention in the UK. Topiramate (brand name Topamax) is an anticonvulsant licensed by the MHRA, and alopecia is a recognised adverse effect listed in its Summary of Product Characteristics. The type of hair loss most commonly associated with topiramate is telogen effluvium — a diffuse, temporary shedding caused by disruption to the normal hair growth cycle. This article explains how common this side effect is, what you can do to manage it, when to seek medical advice, and what alternative treatments your specialist may consider.

Does Topiramate (Topamax) Cause Hair Loss?

Yes, hair loss (alopecia) is a recognised adverse effect of topiramate listed in its MHRA-approved SmPC, most commonly presenting as telogen effluvium — a diffuse, reversible shedding that is generally not indicative of a serious problem.

Experiencing these side effects? Our pharmacists can help you navigate them →

Topiramate, commonly known by the brand name Topamax, is an anticonvulsant medication licensed in the UK for the treatment of epilepsy and, in adults, for the prevention of migraines. According to its Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), topiramate works primarily by blocking voltage-dependent sodium channels, enhancing gamma-aminobutyric acid (GABA-A) activity, and antagonising AMPA/kainate glutamate receptors — mechanisms that reduce abnormal neuronal firing. It is also a weak inhibitor of certain carbonic anhydrase isoenzymes. Beyond its licensed indications, topiramate is sometimes used off-label; it is important to note that the combination product phentermine–topiramate is not licensed in the UK, so any use of topiramate for weight management in the UK is off-label.

Hair loss (alopecia) is listed as a recognised adverse effect of topiramate in the MHRA-approved SmPC. The type of hair loss most commonly associated with topiramate is telogen effluvium — a diffuse, non-scarring shedding of hair that occurs when a physiological or pharmacological stressor disrupts the normal hair growth cycle, pushing a greater proportion of hairs into the resting (telogen) phase prematurely.

Not everyone taking topiramate will experience hair loss, and the condition is generally considered reversible. The precise mechanism by which topiramate triggers telogen effluvium is not fully established; it may relate to its broad effects on cellular metabolism, though claims about specific effects on nutrient absorption are not well evidenced and should not be overstated. Patients should be reassured that this side effect, whilst distressing, does not typically indicate a serious underlying problem with the medication's therapeutic action.

Patients and carers are encouraged to report any suspected side effects — including hair loss — via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Not sure if this is normal? Chat with one of our pharmacists →

How Common Is Hair Loss With Topiramate?

Alopecia is classified as 'uncommon' with topiramate, affecting 1 in 1,000 to 1 in 100 users, with onset typically two to four months after starting treatment or a dose increase.

According to the UK SmPC for topiramate, alopecia is classified as an uncommon adverse effect, meaning it occurs in between 1 in 1,000 and 1 in 100 people taking the medication. This is an important distinction from some older or non-UK sources that may use different frequency classifications. The true incidence in clinical practice may vary depending on dose, duration of treatment, and individual patient factors such as nutritional status, hormonal profile, and genetic predisposition to hair thinning.

There is some clinical evidence to suggest that hair loss may be more noticeable at higher doses, though robust comparative data are limited. Patients prescribed topiramate for epilepsy — who may require doses of 200–400 mg per day — may be at greater risk compared with those on lower doses used for migraine prophylaxis (typically 25–100 mg per day). The onset of shedding typically occurs two to four months after starting the medication or following a dose increase, which is consistent with the delayed nature of telogen effluvium as described in dermatological guidance from the British Association of Dermatologists (BAD) and the Primary Care Dermatology Society (PCDS).

It is also important to consider that hair loss can have multiple concurrent causes. Conditions such as hypothyroidism, iron deficiency anaemia, polycystic ovary syndrome (PCOS), and significant psychological stress can all independently cause or worsen hair shedding. In patients with epilepsy or chronic migraine, these comorbidities are not uncommon. Therefore, attributing hair loss solely to topiramate without appropriate investigation may lead to missed diagnoses. A thorough clinical assessment is always warranted before concluding that topiramate is the definitive cause.

Managing Hair Loss While Taking Topiramate

Management includes nutritional assessment, gentle hair care, monitoring for weight loss, and discussing a possible dose review with your clinician — never stop topiramate abruptly without medical advice.

If you notice increased hair shedding whilst taking topiramate, there are several practical steps that may help reduce its impact. Importantly, do not stop taking topiramate without first speaking to your prescribing doctor, as abrupt discontinuation can trigger seizures in people with epilepsy and may worsen migraine frequency.

The following measures are commonly recommended to support hair health during treatment:

• Nutritional assessment: Ensure adequate intake of protein, iron, zinc, and B vitamins — all of which are important for healthy hair growth. A balanced diet rich in lean proteins, leafy greens, and wholegrains is advisable. Your GP may recommend blood tests to check for deficiencies before starting any supplements. If you are considering nutritional supplements, seek medical advice first; high-dose biotin (vitamin B7) in particular can interfere with certain laboratory assays, including thyroid function tests and troponin assays, potentially leading to misleading results.

• Weight and appetite monitoring: Topiramate can reduce appetite and cause weight loss, which may itself contribute to telogen effluvium. If you have noticed significant unintentional weight loss, discuss this with your GP or specialist.

• Gentle hair care: Avoid excessive heat styling, tight hairstyles, and harsh chemical treatments, which can exacerbate fragile hair. Use mild shampoos and handle hair gently.

• Dose review: In some cases, a clinician may consider whether a dose reduction is clinically appropriate. Even a modest reduction in topiramate dose may lessen the severity of hair shedding without compromising seizure control or migraine prevention.

• Monitoring: Keep a simple diary noting the degree of shedding, any dietary changes, and stress levels. This information can be valuable when discussing the issue with your GP or neurologist.

There is currently no specific licensed treatment for topiramate-induced hair loss in the UK. Topical minoxidil is licensed for androgenetic alopecia but has not been formally evaluated for drug-induced telogen effluvium; its use in this context would be off-label and should only be considered following specialist advice.

Important safety information for women of childbearing potential: The MHRA has issued safety guidance on topiramate use in pregnancy. Topiramate is contraindicated during pregnancy for migraine prophylaxis, and females of childbearing potential should use effective contraception throughout treatment. Your prescriber should discuss the MHRA's Pregnancy Prevention Programme (PPP) materials with you. If you are planning a pregnancy or think you may be pregnant, contact your doctor promptly before making any changes to your medication.

When to Speak to Your GP or Specialist

Seek prompt medical review if hair loss is severe, rapidly progressive, accompanied by bald patches, scalp changes, or systemic symptoms such as fatigue or cold intolerance that may suggest an underlying condition.

Whilst mild, diffuse hair shedding associated with topiramate is generally not a medical emergency, there are circumstances in which prompt medical review is strongly advised. You should contact your GP or specialist if:

• Hair loss is severe, rapidly progressive, or accompanied by bald patches (which may suggest alopecia areata or another dermatological condition)

• You notice scalp pain, redness, scaling, or scarring, which are red-flag features that warrant prompt dermatology review as they may indicate a scarring alopecia requiring urgent assessment

• You notice hair loss alongside other new symptoms such as fatigue, weight changes, cold intolerance, or irregular periods, which could indicate an underlying thyroid or hormonal disorder

• Hair shedding begins shortly after a dose increase, as this may warrant a clinical review of your treatment regimen

• You are experiencing significant psychological distress as a result of hair loss — this is a valid and important reason to seek support

• You are considering stopping topiramate for any reason — never do so without medical guidance, particularly if it is prescribed for epilepsy

Your GP may arrange blood tests including a full blood count, ferritin, thyroid function tests (TFTs), and vitamin D levels to exclude other contributory causes. Depending on your clinical history, B12, folate, or other investigations may also be considered. If the hair loss is thought to be drug-related and is significantly affecting your quality of life, a referral to a dermatologist (hair disorders clinic) via NHS pathways may be appropriate. In cases where topiramate is being used for epilepsy, your neurologist should be involved in any decision to alter or switch medication.

Alternatives and What NICE Guidelines Recommend

For migraine prevention, NICE NG193 recommends propranolol as an evidence-based alternative if topiramate is not tolerated; for epilepsy, alternatives such as lamotrigine or levetiracetam may be considered under specialist supervision.

If hair loss is confirmed to be related to topiramate and is considered clinically significant, your specialist may discuss alternative medications. The appropriate alternative will depend on the underlying condition being treated.

For epilepsy, NICE guideline NG217 (Epilepsies in children, young people and adults, 2022) outlines a range of antiepileptic drugs (AEDs) as options depending on seizure type. Alternatives to topiramate may include lamotrigine or levetiracetam, among others. Sodium valproate carries its own significant risks — particularly in women and girls of childbearing potential — and is subject to the MHRA's Valproate Pregnancy Prevention Programme; it should only be used when other options are unsuitable and with full awareness of the risks. Any switch in AED therapy must be managed carefully and gradually under specialist supervision to minimise seizure risk.

For migraine prevention, NICE guideline NG193 (Headaches in over 12s: diagnosis and management, 2021) recommends offering topiramate or propranolol as first-line preventive options. If topiramate is not tolerated due to side effects such as hair loss, propranolol (a beta-blocker) is an evidence-based alternative, provided there are no contraindications. Amitriptyline (a tricyclic antidepressant) and candesartan (an angiotensin receptor blocker) may be considered off-label where first-line options are unsuitable or not tolerated. It is important to note that gabapentin should not be offered for migraine prophylaxis, in line with NICE NG193 recommendations. For patients with chronic migraine meeting specific criteria, NICE technology appraisals also support the use of onabotulinumtoxinA or CGRP monoclonal antibodies where appropriate.

As noted above, topiramate is contraindicated in pregnancy for migraine prophylaxis in line with MHRA guidance, and females of childbearing potential must use effective contraception and be enrolled in the Pregnancy Prevention Programme. This safety consideration is relevant when weighing up whether to continue or switch treatment.

Ultimately, the decision to continue, adjust, or switch from topiramate should always be made collaboratively between the patient and their healthcare team, weighing the therapeutic benefits against the impact of side effects on quality of life. Hair loss, whilst distressing, must be balanced against the serious risks of uncontrolled epilepsy or debilitating migraines. Open communication with your GP or specialist is the most important step in finding the right solution for you.

Frequently Asked Questions